Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study

A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event

(2016) Ruben G.W. Quek et al.   AMERICAN JOURNAL OF CARDIOLOGY

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

(2016) Jie Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration

(2015) Iris Navarro-Millán et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

(2015) Cem Gabay et al.   ANNALS OF THE RHEUMATIC DISEASES

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

(2015) Camille Roubille et al.   ANNALS OF THE RHEUMATIC DISEASES

Active-comparator design and new-user design in observational studies

(2015) Kazuki Yoshida et al.   Nature Reviews Rheumatology

Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non-Rheumatoid Arthritis Patients

(2015) Katherine P. Liao et al.   Arthritis & Rheumatology

An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy

(2015) Vijay U. Rao et al.   Arthritis & Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims

(2014) H. Kumamaru et al.  

Tumor Necrosis Factor-  Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study

(2014) R. J. Desai et al.   JOURNAL OF RHEUMATOLOGY

Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs

(2013) Daniel H. Solomon et al.   AMERICAN JOURNAL OF MEDICINE

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

(2013) Jamie Robertson et al.   Nature Reviews Rheumatology

Metrics for covariate balance in cohort studies of causal effects

(2013) Jessica M. Franklin et al.   STATISTICS IN MEDICINE

Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments

(2012) Sebastian Schneeweiss et al.   BMC Medical Research Methodology

One-to-many propensity score matching in cohort studies

(2012) Jeremy A. Rassen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data

(2012) Susan E. Andrade et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

(2011) E. Myasoedova et al.   ANNALS OF THE RHEUMATIC DISEASES

A combined comorbidity score predicted mortality in elderly patients better than existing scores

(2011) Joshua J. Gagne et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Validation of rheumatoid arthritis diagnoses in health care utilization data

(2011) Seo Young Kim et al.   ARTHRITIS RESEARCH & THERAPY

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis

(2010) J. D. Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity

(2010) D. H. Solomon et al.   ANNALS OF THE RHEUMATIC DISEASES

Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

(2010) Peter C. Austin   PHARMACEUTICAL STATISTICS

Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

(2010) Cheryl Barnabe et al.   ARTHRITIS CARE & RESEARCH

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies

(2008) J. Antonio Aviña-Zubieta et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study

(2008) Gladys Ting et al.   ARTHRITIS RESEARCH & THERAPY